What is the price of POINT Biopharma Global Inc. (PNT)

The price of POINT Biopharma Global Inc. (PNT) is $12.50

What is the market cap of POINT Biopharma Global Inc. (PNT)

The market cap of POINT Biopharma Global Inc. (PNT) is $708.42M

POINT Biopharma Global Inc. (PNT) Shares Outstanding

POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors. Beyond these late-stage programs, the company's pipeline includes earlier-stage product candidates such as PNT2001, a next-generation PSMA-targeting agent undergoing preclinical studies for non-metastatic castration-sensitive prostate cancer, and PNT-2004, a program focused on fibroblast activation protein-alpha (FAP-a) with broad potential across multiple tumor types, also in preclinical development. Additionally, POINT Biopharma is actively developing further drug candidates utilizing its CanSEEK technology, which it has sub-licensed from Bach Biosciences LLC and Avacta Life Sciences Limited. The company was established in 2019 and is headquartered in Indianapolis, Indiana.

Year	Shares Outstanding	Change
Not enough data for the provided dates.

Year

Shares Outstanding

Change

Not enough data for the provided dates.

Company	Shares Outstanding	Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	478.91M	-	AU
Moderna, Inc. MRNA.US	396.00M	-	US
Lonza Group AG LONN.SW	-	-	CH

Company

Shares Outstanding

Difference

Country